A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)

AIDS Research and Human Retroviruses

Volumn 11, Issue 3, 1995, Pages 373-381

  Pialoux, Gilles ^a   Excler, Jean Louis ^b   Rivière, Yves ^a   Gonzalez Canali, Gustavo ^a   Feuillie, Vincent ^a   Coulaud, Pierre ^a   Gluckman, Jean Claude ^c   Matthews, Thomas J ^d   Meignier, Bernard ^b   Kieny, Marie Paule ^e   Gonnet, Pascale ^b   Diaz, Isabelle ^b   Méric, Claude ^b   Paoletti, Enzo ^f   Tartaglia, James ^f   Salomon, Hervé ^b   Plotkin, Stanley ^b  

^a INSTITUT PASTEUR   (France)

^b Pasteur Mérieux Serums & Vaccins ^*  (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d DUKE UNIVERSITY   (United States)

^e TRANSGENE S A   (France)

^f Virogenetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROCARBON OIL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MINERAL OIL; MONTANIDE ISA 51; RECOMBINANT GLYCOPROTEIN GP 160; RECOMBINANT VACCINE; SORBITAN ESTER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNIZATION; INJECTION PAIN; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; T LYMPHOCYTE SUBPOPULATION; VACCINIA; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANIMALS; AVIPOXVIRUS; CANARIES; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; IMMUNIZATION, SECONDARY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROTEIN PRECURSORS; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 0028986509     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.373     Document Type: Article

References (27)

1. Fast EP and Walker MC: Human trials in experimental AIDS vaccines. AIDS 1993;7:S147-S159.
2. Orentas RJ, Hildreth JEK, Obah E, Polydefkis M, Smith GE, Clements ML, and Siliciano RF: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gpl60 subunit vaccine. Science 1990;248:1234-1237.
3. Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, and Siliciano RF: Comparative clonal analysis of human immunodeficiency virus type 1 (HlV-l)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-1542.
4. Hu SL, Zarling JM, Chinn J, Travis BM, Moran PA, Sias J, Kuller L, Morton WR, Heidecker G, and Benveniste RE: Protection of macaques against AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoprotein of simian type D retrovirus. Proc Natl Acad Sci USA 1989;86:7213-7217.
5. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gpl60. Science 1992;225:456-459.
6. Chakrabarty S, Robert-Guroff M, Wong-Stall F, Gallo RC, and Moss B: Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (London) 1986;320:535-537.
7. Hu SL, Kosowski SG, and Dalrymple JM: Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature (London) 1986;320:537-539.
8. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, and Corey L: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-572.
9. Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, and Letvin NL: Recombinant virus vaccine-induced SlV-spe-cific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-443.
10. Gotch FM, Hovell R, Delchambre M, Silvera P, and McMichael AJ: Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus. AIDS 1991;5:317-320.
11. Zarling JM, Eichberg JW, Moran PA, McClure J, Sridar P, and Hu SL: Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol 1987;139:988-990.
12. Hu SL, Klaniecki J, Dykers T, Sridhar P, and Travis B: Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gpl60. AIDS Res Hum Retroviruses 1991;7:615-620.
13. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced inmiunity to HIV envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HTV envelope and boosting with gpl60 protein. Proc Natl Acad Sci USA 1993;90:1882-1886.
14. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF. Gorse GJ, Schwartz DM, Keefer MC. Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu SL, Smith GE, Fast PE, and Koff WC: Augmentation of HIVl neutralizing antibody by priming with gpl60 recombinant virus and boosting with rgpl60 in vaccinia-naive adults. J Infect Dis 1993;167:533-537.
15. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, and Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-1432.
16. Taylor J, Weinberg R, Tartaglia J. Richardson C, Alkhatib G, Briedis D, Norton E, and Paoletti E: Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992;187:321-328.
17. Baxby D and Paoletti E: Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992;10:8-9.
18. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, and Paoletti E: The complete DNA sequence of vaccinia virus. Virology 1990;179:247-266.
19. Kieny MP, Lathe R, Rivière Y, Dott K, Schmitt D, Girard M, Montagnier L, and Lecocq JP: Improved antigenicity of the HIV Env protein by cleavage site removal. Protein Eng 1988;2:219-225.
20. Bahraoui E, Yagello M, Billaud JN, Sabatier JM, Guy B, Muchmore E, Girard M, and Gluckman JC: Immunogenicity of the human immunodeficiency virus (HIV) recombinant zie/gene product. Mapping of T-cell and B-cell epitopes in immunized chimpanzees. AIDS Res Hum Retroviruses 1990;6:1087-1098.
21. McChesney M, Tanneau F, Regnault A, Sansonetti P, Montagnier L, Kieny MP, and Rivière Y: Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the Env amino-terminal signal sequence. Eur J Immunol 1990;20:215-220.
22. Robertson MN, Buysene F, Kieny MP, and Rivière Y: Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1 Lai is more commonly recognized than HIV-Imn. j Infect Dis 1994;169:274-280.
23. Morrison LA, Braciale VL, and Braciale TJ: Antigen form influences induction and frequency of. influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes. J Immunol 1988;141r363-368.
24. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ, Schwartz DH, Agosti JM, Femie BF, Stablein DM, Montefiori DC, Lambert JS, Hu SL, Esterlitz JR, Lawrence DN, and Koff WC: Vaccination of vaccinia-naive adults with HIV type 1 gpl60 recombinant vaccinia virus in a blinded, controlled randomized clinical trial. J Infect Dis 1992;166:244-252.
25. Salmon-Céron D, Excler JL, Sicard D, Blanche P, Finkielstzjen L, Gluckman JC, Autran B, Matthews TJ, Meignier B, Kieny MP, Valentin C, Gönnet C, Diaz I, Salomon H, Plotkin S, the Agis Group, and I'Agence Nationale de Recherche sur le SIDA: Safety and immunogenicity of a recombinant HIV-1 gpl60 followed by a V3 synthetic peptide in HIV negative volunteers. AIDS Res Hum Retroviruses 1995;11; in press.
26. McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, and Greenberg P: Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994;169:41-47.
27. Nixon DF and McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991;5:1049-1059.